Results 181 to 190 of about 5,508,271 (271)

Usefulness of intraoperative transesophageal echocardiography for hemodynamic management of liver transplantation in a patient with massive polycystic liver disease: a case report. [PDF]

JA Clin Rep, 2023
Ueda Y, Kawaji T, Komura H, Hara Y, Kuriyama N, Nakamura T, Nishida O.   +6 more
europepmc   +1 more source

Iron and Other Metal Ions in Human Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
Iron, copper, zinc, and calcium orchestrate cellular function through distinct yet cooperative mechanisms: redox‐active iron and copper cycle between oxidation states to act as Fenton catalysts and electron carriers in oxidative phosphorylation (OXPHOS); redox‐inert zinc serves as a structural component of zinc‐finger proteins and a catalytic cofactor ...
Xiaofeng Dai, Jitian Li
wiley   +1 more source

Adult polycystic liver disease in childhood. A case report

, 1986
A case of adult type polycystic liver disease in a child is reported. The entire right hepatic lobe was involved whereas the left lobe was normal. Spleen, kidneys and pancreas did not show cystic alterations.
CATERINO, Salvatore, CAVALLARO, Antonino, GALLO, Pietro, M. Palumbo, G. Fariello, G. Alessi, M. Marcellini, A. M. Costantini Costabile   +7 more
core  

Somatostatin analog therapy in delaying progression of polycystic liver disease: A meta-analysis with trial sequential analysis. [PDF]

ILIVER
Beshr MS, Shembesh RH, Sawaf B, Abbarh S, Abu-Rumaileh M, Tincopa M, Elhadi M.   +6 more
europepmc   +1 more source

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

Medical Management of Polycystic Liver Disease: A Position Statement From the European Reference Network on Hepatological Diseases. [PDF]

Liver Int
Heinrich S, de Matos AMC, Colmenero J, Elsharkawy AM, Fraňková S, Halbritter J, Mrzljak A, Müller RU, Pereira R, Strnad P, Teemer CAJ, Verbeek J, Wronka KM, Nevens F, Taubert R, Drenth JPH, European Reference Network on Hepatological Liver Diseases (ERN RARE‐LIVER).   +16 more
europepmc   +1 more source

Tamoxifen for the treatment of polycystic liver disease: A case report. [PDF]

Medicine (Baltimore), 2021
Aapkes SE, Bernts LHP, van den Berg M, Gansevoort RT, Drenth JPH.   +4 more
europepmc   +1 more source

Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review

Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1308-1317, October 2026.
Abstract Humans have a primitive defense mechanism called metabolic adaptation that slows voluntary weight loss. It works by downregulating hormones that reduce food intake and by lowering the metabolic rate. Second‐generation GLP‐1 receptor agonists, such as semaglutide or tirzepatide, promote weight loss by targeting this hormonal system to control ...
Ken Fujioka
wiley   +1 more source

Laparoscopic Lin operation for the treatment of polycystic liver disease

, 1998
Non parasitic hepatic cysts are a clinical entity that is often associated with polycystic kidney disease. We report the case of a 75 year-old woman who presented with symptomatic but non complicated polycystic liver disease.
U. Cioffi, M. De Simone
core  

Key Aspects in the Nutritional Management of Polycystic Liver Disease Patients. [PDF]

Nutrients
Khan S, Di Cola S, Lai S, Ferri F, Cardinale V, Merli M.   +5 more
europepmc   +1 more source